AquAdvantage salmon is a genetically modified (GM) Atlantic salmon developed by AquaBounty Technologies. A growth hormone-regulating gene from a Pacific Chinook salmon, with a promoter from an ocean pout, was added to the Atlantic salmon's 40,000 genes. This gene enables it to grow year-round instead of only during spring and summer. The purpose of the modifications is to increase the speed at which the fish grows without affecting its ultimate size or other qualities. The fish grows to market size in 16 to 18 months rather than three years. The latter figure refers to varieties whose growth rate has already been improved by 2:1 as a result of traditional selective breeding. Conventional salmon growers publicly challenged the claimed growth rates.
AquAdvantage salmon are triploid (having three sets of chromosomes whereas most animals have two sets) female Atlantic salmon (Salmo salar), with a single copy of the opAFP-GHc2 construct, which codes for a promoter sequence from ocean pout directing production of a growth hormone protein using coding sequence from Chinook salmon. This transgene allows the fish to achieve accelerated growth rates. Induction of triploidy in nearly 99% of the salmon by treatment of batches of eggs renders most of the fish sterile, reducing the risk of interbreeding with wild-type fish and further increasing growth by removing the stress of reproduction.
AquAdvantage built a 100-ton/year aquaculture facility in landlocked highlands in Panama, a fraction of the 1.6 million ton/year global output of farmed Atlantic salmon. The company promoted its product as a way to re-establish a domestic U.S. salmon industry in place of imported aquaculture fish from Chile and Norway, reducing transportation costs and carbon footprint.